JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Establishment of a prognostic risk model for osteosarcoma and mechanistic investigation

  • 0Department of Sports Medicine, Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Frontiers in Pharmacology +

|

May 9, 2024

|

May 9, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Charged multivesicular body protein 4C (CHMP4C) promotes osteosarcoma (OS) invasion and spread by activating the Wnt/β-catenin pathway. Targeting CHMP4C may mitigate bone destruction in aggressive OS, offering new therapeutic strategies.

Area Of Science

  • Oncology
  • Immunology
  • Molecular Biology

Background

  • Osteosarcoma (OS) is an aggressive bone cancer prone to recurrence and metastasis.
  • Understanding the immune mechanisms underlying OS progression is crucial for developing effective treatments.
  • Identifying specific OS markers can help mitigate bone destruction and improve patient outcomes.

Purpose Of The Study

  • To investigate the immune mechanism of osteosarcoma (OS)-specific markers.
  • To identify a key gene involved in OS progression and bone destruction.
  • To explore the role of charged multivesicular body protein 4C (CHMP4C) in OS immune regulation and metastasis.

Main Methods

  • Analysis of gene expression profiles from the GEO database (GSE126209) using WGCNA, PPI, LASSO, and survival analysis.
  • Assessment of CHMP4C expression in OS cell lines (MG63, U2OS, HOS) and human osteoblasts (hFOB1.19) via RT-qPCR and immunofluorescence.
  • In vitro functional assays (CCK-8, transwell, colony formation) and in vivo OS xenograft studies in nude mice.

Main Results

  • CHMP4C was identified as a key gene positively correlated with OS.
  • Overexpression of CHMP4C upregulated p-GSK3β and β-catenin, promoting OS cell proliferation and migration.
  • High CHMP4C expression accelerated OS xenograft growth in vivo, confirming its role in promoting tumor progression.

Conclusions

  • CHMP4C acts as a specific immunomodulatory gene in osteosarcoma.
  • CHMP4C activates the Wnt/β-catenin signaling pathway by increasing GSK3β phosphorylation.
  • Targeting CHMP4C may offer a novel therapeutic strategy to inhibit OS invasion and metastasis.

Keywords: